1Nikolsky E, Sadeghi HM, Effron MB, et al. Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction [ J]. Am J Cardiol, 2005, 96(4) : 474 -481.
2Huxtable LM, Tafreshi M J, Rakkar AN, et al. Frequency and management of thrombocytopenia with the glycoprotein Ⅱb/Ⅲa receptor antagonists [ J ]. Am J Cardiol, 2006, 97 ( 3 ) : 426 - 429.
3Tcheng JE, Kereiakes D J, Lincoff AM, et al. Abciximab readministration: results of the ReoPro Readministration Registry [ J ]. Circulation,2001, 104 ( 8 ) : 870 - 875.
4ESPRIT-Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT) : a randomised, placebocontrolled trial [ J ]. Lancet, 2000, 356 (9247) : 2037 - 2044.
5IMPACT-ⅡInvestigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention [ J ]. Lancet, 1997, 349 ( 9063 ) : 1422 - 1428.
6Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISMPLUS) Study Investigators. Inhibition of the platelet glycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non- Q-wave myocardial infarction [ J ]. N-Engl-J-Med, 1998, 338 (21) :1488 - 1497.
7The RESTORE Investigators. Effects of platelet glycoprotein Ⅱb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty[ J]. Circulation, 1997,96 (5) : 1445 - 1453.
8PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspizin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management [ J]. N Engl J Med,1998,338(21 ) : 1498 - 1505.
3Beers MH. The Merck Manual of Diagnosis and Therapy (18 nd Ed) [M]. Whitehouse NJ: Merck Research Laboratories, 2006: 1064- 1070.
4Balamuthusamy S, Arora R. Hematologic adverse effects of clopidogrel [J]. Am J Ther, 2007; 14: 106-112.
5Bougie DW, Wilker PR, Wuitschick ED,et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand - occupied GPⅡb/Ⅲa [ J ]. Blood, 2002 ; 100:2071 - 2076.
6Ahmed I, Majeed A, Powell R. Heparin induced thrombocytopenia: diagnosis and management update[ J]. Postgrad Med J,2007 ;83:575 - 582.
5van den Bemt PM, Meyboom RH, Egberts AC. Drug induced immune thrombocytopenia[J]. Drug Saf, 2004,27 ( 15 ) : 1243 1252.
6Kaufman DW, Kelly JP, Johannes CB, et al. Acute thrombo cytopenic purpura in relation to the use of drugs[J]. Blood. /993,82(9) :2714-2718.
7Aster RH,Curtis BR, McFarland JG, et al. Drug induced im- mune thrombocytopenia: pathogenesis, diagnosis, and man agement[J]. J Thromb Haemost,2009,7(6) :911-918.
8Visentin GP,Newman PJ, Aster RH. Characteristics of qui- nine and quinidine-induced antibodies specific for platelet glyco proteins Ⅱb and Ⅲa[J]. Blood, 1991, 77(12) : 2668-2676.
9Bougie DW,Wilker PR, Aster RH. Patients with quinine in- duced immune thrombocytopenia have both"drug-dependem" and "drug specific" antibodies[J]. Blood,2006,108:922-927.
10Perdomo J, Yah F, Ahmadi Z, el at. Quinine induced lhrom boeytopenia: drug-dependent GPIb/IX antibodies inhibil megakaryoeyte and proplatelet production in vitro[J]. Blood, 2011,117(22):2275-2286.
